Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNAZ trial of zanubrutinib plus rituximab for anti-MAG neuropathy
NL-OMON52317Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in anti-myelin-associated glycoprotein neuropathy and monoclonal gammopathy of undetermined significance (MGUS), sponsored by University Medical Center Utrecht. Primary endpoint: Neurological functional outcome by iRODS. Planned start Aug 2022; status: withdrawn.
02
Drugs
zanubrutinib
03
Conditions
anti-myelin-associated glycoprotein neuropathymonoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on NL-OMON52317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52317.